Study assesses outcomes of therapies with novel agents
Autologous anti-CD19 agent produces impressive survival improvements
Interim results of phase 2 trial are promising
Study results from ASH 2019 shed light on treatment
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Non-home discharge and higher ECOG status associated with IP/IV chemotherapy non-completion
Algorithm reveals many features not appreciated by the unaided eye
Greater weight means less sleep, lower quality of life
Instrument aids natural orifice endoluminal surgery
First step toward testing therapeutics
Urine prohibitin identified as a prognostic biomarker in Wilms’ tumor
Advertisement
Advertisement